- Home
- GYRE vs BH Comparison
GYRE vs BH Comparison
Compare GYRE & BH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- BH
- Stock Information
- Founded
- GYRE 2002
- BH 1934
- Country
- GYRE United States
- BH United States
- Employees
- GYRE N/A
- BH N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- BH Restaurants
- Sector
- GYRE Health Care
- BH Consumer Discretionary
- Exchange
- GYRE Nasdaq
- BH Nasdaq
- Market Cap
- GYRE 897.1M
- BH 904.4M
- IPO Year
- GYRE N/A
- BH N/A
- Fundamental
- Price
- GYRE $8.21
- BH $287.23
- Analyst Decision
- GYRE
- BH
- Analyst Count
- GYRE 0
- BH 0
- Target Price
- GYRE N/A
- BH N/A
- AVG Volume (30 Days)
- GYRE 80.3K
- BH 21.0K
- Earning Date
- GYRE 08-11-2025
- BH 08-08-2025
- Dividend Yield
- GYRE N/A
- BH N/A
- EPS Growth
- GYRE N/A
- BH N/A
- EPS
- GYRE 0.02
- BH 146.55
- Revenue
- GYRE $102,189,000.00
- BH $377,176,000.00
- Revenue This Year
- GYRE $21.04
- BH N/A
- Revenue Next Year
- GYRE $89.64
- BH N/A
- P/E Ratio
- GYRE $170.09
- BH $22.12
- Revenue Growth
- GYRE N/A
- BH 4.14
- 52 Week Low
- GYRE $6.11
- BH $159.69
- 52 Week High
- GYRE $19.00
- BH $328.65
- Technical
- Relative Strength Index (RSI)
- GYRE 60.94
- BH 44.80
- Support Level
- GYRE $6.62
- BH $273.39
- Resistance Level
- GYRE $7.47
- BH $288.49
- Average True Range (ATR)
- GYRE 0.46
- BH 10.84
- MACD
- GYRE 0.12
- BH -3.74
- Stochastic Oscillator
- GYRE 99.09
- BH 29.21
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.